Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and REGEMAT 3D, a company at the forefront of personalized biofabrication solutions, have entered into a non-exclusive distribution agreement, in a response to the growing demand, and to serve a broader life sciences customer base of industry partners and academic institutions in the European bioprinting and drug testing market.
Development and optimization of new biomaterials is a paramount step in the progress of tissue engineering and regenerative medicine, especially when it comes to the success of clinical therapeutic approaches. Human-derived biomaterials better mimic the physical and chemical properties of natural human tissues and avoid risks associated with xenogenic biomaterials, such as immunological complications or risk of disease transmission. These biomaterials have the potential to reduce the number of animals employed for research and accelerate the translation of research results into clinics.
REGEMAT 3D is amongst the top emerging 3D bioprinting companies in the world and has clients in more than 28 countries. It is a pioneer of customized design and development of 3D bioprinters and bioreactors for tissue engineering applications, products tailored to specific research groups, and specific research applications. In response to the current market demand, REGEMAT 3D is planning to extend its biomaterials portfolios, focusing on tissue-specific advanced bioinks. The company has recently implemented a cell culture and biofabrication lab in its headquarters to validate products prior to market release, execute R&D for individual and collaborative projects, and give technical support to its network of clients.
Humabiologics is the first company in the world to develop and commercialize a wide range of high-quality, supply-stable, and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue and disease modeling, and drug screening. The company’s products are extracted from nutrient-rich human tissue sourced strictly from tissue partners who comply with all the requirements for transplantable human tissue. Human collagen type I, human gelatin, and human extracellular matrix can be found among the biomaterials offered in their catalog. REGEMAT 3D will provide access to those products to bioprinting and drug testing researchers and industry partners in Europe, through the company’s website and network.
Some of the biomaterials distributed by REGEMAT 3D will include HumaDerm (native human skin collagen type I), Huma OsteoGelatin (the first and only human gelatin in the market derived from bone at bloom numbers between 90-300 g to meet translational research and regenerative therapies needs), and HumaMatrix (one of the first commercially available native, human-derived extracellular matrix products).
“Humabiologics continues to grow its network of bioprinting partners around the world. We are excited to partner with REGEMAT 3D, who is considered at the forefront of bioprinting and has been serving the field with bioprinting resources for several years”, said Dr. Mohammad Albanna, Founder, and CEO of Humabiologics. “We look forward to working with the REGEMAT team to respond to the growing demand of clinically relevant biomaterials needed to create human tissue models to improve the process of drug testing and reduce animal testing in the future.”
Humabiologics and REGEMAT 3D share the common mission of leading regenerative medicine innovation through the development of new technologies that are aimed to materialize research projects into functional clinical solutions – address debilitating diseases and improve the quality of life for patients all over the world.
“We are delighted with the achievement that this collaboration agreement means to both our companies. It is an absolute honor to be able to coordinate a project with a world-renowned company such as Humabiologics, particularly when we pursue the same objective: open doors to the translation of regenerative medicine innovative research into clinics”, said Manuel Figueruela, Executive Managing Director of REGEMAT 3D. “In that sense, we are certain that the development, production, and commercialization of high-quality human-derived printable biomaterials represents a turning point for health-care research and industry, and, hand in hand with Humabiologics, we are proud to contribute to this progress.”